Oncolytics Biotech (ONCY) Return on Capital Employed (2010 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Return on Capital Employed of 394.52% for Q3 2025, down 1302.0% year-over-year from 32.82% in Q3 2024, and down 62.65% quarter-over-quarter from 242.56% in Q2 2025.
Oncolytics Biotech (ONCY) Return on Capital Employed (2010 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Return on Capital Employed for 16 consecutive years, with 394.52% the latest figure, recorded in Q3 2025.
- In Q3 2025, Return on Capital Employed fell 1302.0% year-over-year to 394.52%; the TTM figure through Sep 2025 stood at 394.52% (down 1302.0% YoY), while the FY2025 annual figure was 652.77%, down 49516.0% from the prior year.
- Return on Capital Employed declined to 394.52% in Q3 2025 per ONCY's latest filing, from 242.56% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 76.93% in Q3 2021 and bottomed at 491.07% in Q4 2024.
- Historically, Return on Capital Employed has averaged 160.71% across 5 years, with a median of 133.35% in 2022.
- Annual changes were most pronounced in 2021 — Return on Capital Employed surged 14078 bps — and 2024, when it tumbled 32897 bps.
- Oncolytics Biotech's Return on Capital Employed stood at 83.63% in 2021, then plunged by 47 bps to 123.06% in 2022, then tumbled by 32 bps to 162.1% in 2023, then plunged by 203 bps to 491.07% in 2024, then advanced by 20 bps to 394.52% in 2025.
- Business Quant data shows ONCY's Return on Capital Employed at 394.52% in Q3 2025, 242.56% in Q2 2025, and 491.07% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | -1,254.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,258.46% |
| Sep 30, 2025 | -394.52% |
| Jun 30, 2025 | -242.56% |
| Dec 31, 2024 | -491.07% |
| Sep 30, 2024 | -381.50% |
| Jun 30, 2024 | -277.33% |
| Dec 31, 2023 | -162.10% |
| Sep 30, 2023 | -176.85% |
| Jun 30, 2023 | -148.37% |
| Mar 31, 2023 | -129.81% |
| Dec 31, 2022 | -123.06% |
| Sep 30, 2022 | -133.35% |
| Jun 30, 2022 | -96.51% |
| Mar 31, 2022 | -60.28% |
| Dec 31, 2021 | -83.63% |
| Sep 30, 2021 | 76.93% |
| Jun 30, 2021 | 54.77% |
| Mar 31, 2021 | 37.17% |
| Dec 31, 2020 | 51.60% |
| Sep 30, 2020 | -63.85% |